Forte Biosciences (NASDAQ:FBRX) Sets New 12-Month High – Still a Buy?

Shares of Forte Biosciences, Inc. (NASDAQ:FBRX) reached a new 52-week high on Monday . The company traded as high as $76.45 and last traded at $76.45, with a volume of 4174964 shares trading hands. The stock had previously closed at $54.78.

Forte Biosciences News Summary

Here are the key news stories impacting Forte Biosciences this week:

• Positive Sentiment: argenx will acquire all outstanding Forte shares for $77 in cash, giving investors a clear deal-value reference and significantly repricing FBRX above its pre-announcement level. The acquisition also gives argenx access to Forte’s experimental autoimmune therapy FB102, strengthening its immunology pipeline. Reuters article
• Positive Sentiment: The all-cash structure reduces exposure to biotechnology development risk for Forte shareholders, while the premium and strategic interest from argenx provide support for the current valuation. Proactive Investors article
• Neutral Sentiment: FBRX trading volume has been substantially above its average, consistent with merger-related positioning. A significant increase in put-option activity also indicates that some traders are hedging against deal or market risk rather than simply betting on further gains.
• Negative Sentiment: Several shareholder-rights law firms, including Kahn Swick & Foti, are investigating whether the $77 consideration and sale process adequately protect shareholders. Similar investigations by Halper Sadeh, Ademi and Monteverde could create litigation, delay or renegotiation risk, although these announcements do not by themselves indicate that the transaction will fail. Kahn Swick & Foti investigation

Analyst Upgrades and Downgrades

Several equities research analysts have commented on FBRX shares. Wall Street Zen downgraded Forte Biosciences from a “sell” rating to a “strong sell” rating in a report on Saturday. Evercore set a $77.00 price target on Forte Biosciences in a research report on Monday. Barclays lowered Forte Biosciences from an “overweight” rating to an “equal weight” rating and lifted their price target for the stock from $74.00 to $77.00 in a research report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Forte Biosciences in a research note on Wednesday, July 8th. Finally, TD Cowen downgraded shares of Forte Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Monday. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $72.50.

Forte Biosciences Stock Performance

The firm has a market cap of $1.06 billion, a P/E ratio of -16.52 and a beta of 2.85. The stock has a fifty day simple moving average of $28.43 and a 200 day simple moving average of $28.59.

Forte Biosciences (NASDAQ:FBRX) last announced its quarterly earnings results on Monday, May 11th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.08). Research analysts predict that Forte Biosciences, Inc. will post -4.27 earnings per share for the current year.

Institutional Investors Weigh In On Forte Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in FBRX. Royal Bank of Canada grew its holdings in shares of Forte Biosciences by 6.5% in the fourth quarter. Royal Bank of Canada now owns 11,986 shares of the company’s stock worth $327,000 after acquiring an additional 733 shares during the period. Global Retirement Partners LLC bought a new position in Forte Biosciences in the fourth quarter valued at about $27,000. Bank of America Corp DE lifted its holdings in Forte Biosciences by 5,641.8% in the third quarter. Bank of America Corp DE now owns 3,158 shares of the company’s stock valued at $47,000 after acquiring an additional 3,103 shares during the period. Geode Capital Management LLC lifted its holdings in Forte Biosciences by 6.7% in the second quarter. Geode Capital Management LLC now owns 64,110 shares of the company’s stock valued at $829,000 after acquiring an additional 4,028 shares during the period. Finally, Envestnet Asset Management Inc. boosted its position in Forte Biosciences by 23.8% in the third quarter. Envestnet Asset Management Inc. now owns 23,347 shares of the company’s stock worth $350,000 after purchasing an additional 4,491 shares during the last quarter. Hedge funds and other institutional investors own 77.63% of the company’s stock.

Forte Biosciences Company Profile

Forte Biosciences, Inc is a clinical-stage biotechnology company focused on developing innovative treatments to restore skin health by targeting the underlying biology of the skin barrier and microbiome. Headquartered in San Diego, California, Forte leverages proprietary platforms to discover and advance topical live biotherapeutic products and skin barrier therapies aimed at addressing serious dermatological conditions.

The company’s lead product candidate, FB-401, is a topical live biotherapeutic formulation designed to rebalance the skin microbiome in patients with atopic dermatitis.